Abstracts Archive - Page 223 of 2425 - ACR Meeting Abstracts

Abstract Number: 0292 • ACR Convergence 2023
Comparison of Cardiovascular Risk of Myositis Patients and the General Population
Sabina Oreska¹, Hana Storkanova¹, Jaroslav Kudlicka², Vladimir Tuka², Ondrej Mikes², Zdislava Krupickova², Martin Satny², Eva Chytilova², Jan Kvasnicka², Maja Spiritovic³, Barbora Hermankova⁴, Petr Cesak⁵, Marian Rybar⁶, Karel Pavelka¹, Ladislav Senolt⁷, Herman Mann⁸, Jiri Vencovsky¹, Michal Vrablik² and Michal Tomcik¹, ¹Institute of Rheumatology, Prague, Czech Republic, Department of Rheumatology, 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ²3rd Department of Internal Medicine, General University Hospital and 1st Faculty of Medicine, Charles University, Prague, Czech Republic, ³Institute of Rheumatology, Prague, Czech Republic, Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁴Department of Physiotherapy, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁵Department of Human Movement Laboratory, Faculty of Physical Education and Sport, Charles University, Prague, Czech Republic, ⁶Department of Biomedical Technology, Faculty of Biomedical Engineering, Czech Technical University in Prague, Kladno, Czech Republic, ⁷Institute of Rheumatology and Department of Rheumatology, First Faculty of Medicine, Praha, Czech Republic, ⁸Institute of Rheumatology, Praha 2, Czech Republic
Background/Purpose: Cardiovascular (CV) risk due to accelerated atherosclerosis and impaired metabolism can be increased in idiopathic inflammatory myopathies (IIM) on behalf of systemic inflammation, limited…
Abstract Number: 0339 • ACR Convergence 2023
Longitudinal Glucocorticoid Toxicity in Rheumatic Disease Patients (LONG-TOX) and Associations with Quality of Life and Healthcare Resource Utilization: Interim Analysis from a Prospective Cohort
Naomi Patel¹, Aubree McMahon¹, Grace McMahon¹, Sebastian Perez-Espina¹, Isha Jha¹, Adam Jarvie¹ and John Stone², ¹Massachusetts General Hospital, Boston, MA, ²Massachusetts General Hospital Rheumatology Unit, Harvard Medical School, Concord, MA
Background/Purpose: Glucocorticoids (GCs) continue to be the cornerstone of therapy for many rheumatic diseases, though long-term exposure to GCs has been linked to dozens of…
Abstract Number: 0314 • ACR Convergence 2023
Lack of Systemic Effects from Intra-articular XT-150 for the Treatment of Moderate to Severe Pain Due to OA of the Knee: Safety Results from a Phase 2 Trial
Leonard Kapural¹, Stephen D. Collins², Eric Grigsby³, Mark McBride⁴, Jayson Rieger⁵, Morgan Stokes⁶, Howard Rutman⁶ and Flavia Cicuttini⁷, ¹Center for Clinical Research, Winston-Salem, NC, ²Xalud Therapeutics, Inc., Chicago, IL, ³Neurovations Clinical Research, Napa, CA, ⁴Instat Clinical Research, Chatham, NJ, ⁵PBM Capital, Charlottesville, VA, ⁶Xalud Therapeutics, Inc., Berkeley, CA, ⁷Monash University, Melbourne, Australia
Background/Purpose: This study (NCT04124042) was designed to assess the safety, tolerability, and efficacy of XT-150, a non-viral gene therapy, in adult participants with moderate to…
Abstract Number: 0350 • ACR Convergence 2023
Presentation, Management, and Outcomes of Systemic JIA-Associated Lung Disease: A Single Center Experience
Ana Luiza Altaffer¹, Maria Pereira², Marietta De Guzman² and Andrea Ramirez², ¹Baylor College of Medicine, Texas Children's Hospital, Houston, TX, ²Baylor College of Medicine, Houston, TX
Background/Purpose: Interstitial lung disease (ILD) is a rare and severe complication of systemic juvenile idiopathic arthritis (SJIA) that was recognized relatively recently, and its incidence…
Abstract Number: 0499 • ACR Convergence 2023
Durability of Response Among Patients with Psoriatic Arthritis (PsA) Using Biological or Targeted Synthetic Disease-Modifying Antirheumatic Drugs in the CorEvitas PsA/Spondyloarthritis Registry
Alexis R Ogdie¹, Chao Song², Nicole Middaugh³, Maya Marchese³, Melissa Eliot³, Silky Beaty⁴, Robert Low⁴ and Philip J. Mease⁵, ¹University of Pennsylvania, Philadelphia, PA, ²UCB Pharma, Duluth, GA, ³CorEvitas, LLC, Waltham, MA, ⁴UCB Pharma, Smyrna, GA, ⁵Swedish Medical Center/Providence St. Joseph Health and University of Washington School of Medicine, Seattle, WA
Background/Purpose: Improvement in both joint and skin manifestations is an important goal in the treatment of psoriatic arthritis (PsA). This study describes durability of 50%…
Abstract Number: 0297 • ACR Convergence 2023
Characteristics of Anti-MDA-5 Associated Dermatomyositis in Southern California with a Large Hispanic Population: Case Series
Eaman Alhassan¹, Belina Yi², Jack Rodman¹ and Leanna Wise³, ¹University of Southern California, Los Angeles, CA, ²Children's Hospital Los Angeles, Los Angeles, CA, ³LAC+USC/Keck Medicine of USC, Pasadena, CA
Background/Purpose: There is little to no data about the presentation and clinical course of anti-melanoma differentiation-associated gene-5 antibody (anti-MDA-5) dermatomyositis patients in a primarily U.S.…
Abstract Number: 0347 • ACR Convergence 2023
Towards Effective Shared Decision Making – Development and Validation of a Prediction Model for Personalized Probabilities of Side Effects in the Initial Treatment of Juvenile Idiopathic Arthritis
Jonathan Park¹, Thomas Loughin², Andrew Henrey² and Jaime Guzman³, ¹Western University, London, ON, Canada, ²British Columbia Children's Hospital, Vancouver, BC, Canada, ³British Columbia Children's Hospital, Vancouver, BC, Canada
Background/Purpose: Clinical practice guidelines for Juvenile Idiopathic Arthritis (JIA) emphasize the importance of adapting guideline recommendations to each individual patient through shared decision-making among patients,…
Abstract Number: 0349 • ACR Convergence 2023
Disease Activity of Juvenil Idiopathic Arthritis in Transitional Care
Karen Carpio Astudillo¹, Daniel clemente Garulo², Juan Carlos Lopez-Robledillo³, Camille Bourgeois Avella⁴, Laura Trives Folguera⁴, Amparo López López¹, Jose María Alvaro-Gracias⁴, Indalecio Monteagudo Sáez¹ and Juan carlos Nieto-Gonzalez⁵, ¹Hospital General Universitario Gregorio Marañón, Madrid, Spain, ²Pediatric Rheumatology Unit, Hospital Niño Jesús, Madrid, Spain, ³Hospital Infantil Universitario Niño Jesús, Madrid, Spain, ⁴Hospital General Universitario Gregorio Marañon, Madrid, Spain, ⁵Servicio de Reumatología, Hospital General Universitario Gregorio Marañón, Madrid, Spain
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) are a group of heterogeneous arthritis with onset in childhood. According to previous studies, this patients experience an improvement of…
Abstract Number: 0340 • ACR Convergence 2023
Rheumatology Patients’ Experiences of a Nationwide Transition to an Adalimumab Biosimilar: A Cross-Sectional Study
Chiara Gasteiger¹, Maria Lobo², Robin Stanley¹, Lun Shen Wong¹, Rachel Murdoch¹ and Nicola Dalbeth¹, ¹University of Auckland, Auckland, New Zealand, ²Department of Rheumatology, Te Toka Tumai Auckland, Auckland, New Zealand
Background/Purpose: Patients are frequently transitioned to biosimilars to reduce the cost burden of biologics. Brand changes can be daunting for patients who have concerns about…
Abstract Number: 0366 • ACR Convergence 2023
Active Joint Acoustic Emissions on the Achilles Tendon: A Digital Biomarker of Enthesitis Related Arthritis
Quentin Goossens¹, Miguel Locsin², Emily Moise³, Lori Ponder⁴, Omer Inan¹ and Sampath Prahalad⁵, ¹Georgia Institute of Technology, Atlanta, GA, ²Emory University School of Medicine, Atlanta, GA, ³Georgia Institute of Technolgy, Atlanta, GA, ⁴Children's Healthcare of Atlanta, Atlanta, GA, ⁵Emory University School of Medicine, Children's Pediatric Institute, Atlanta, GA
Background/Purpose: Juvenile Idiopathic Arthritis (JIA) is a chronic condition in children that causes joint inflammation. Enthesitis-related arthritis (ERA), a subtype of JIA, affects 10-20% of…
Abstract Number: 0352 • ACR Convergence 2023
Musculoskeletal Ultrasound Findings in Children with Psoriasis
Laura Nedorezov, Tracy Ting and Patricia Vega-Fernandez, Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: The presentation of juvenile psoriatic arthritis (JPsA) in children with psoriasis can be insidious and poses a diagnostic challenge. Musculoskeletal ultrasound (MSUS) has emerged…
Abstract Number: 0345 • ACR Convergence 2023
Jadas10- and cjadas10-based Disease Activity States for Psoriatic Arthritis, Enthesitis-related Arthritis, and Rf+ Polyarthritis
Silvia Maria Orsi¹, Marco Burrone¹, Ana Isabel Rebollo Gimenez², Francesca Ridella¹, Silvia Rosina², Luca Carlini³, Ingrida Rumba-Rozenfelde,⁴, Nahid Shafaie⁵, Tadej Avcin⁶, Pierre Quartier⁷, Nicolino Ruperto⁸, Angelo Ravelli⁹, Marco Gattorno¹⁰ and Alessandro Consolaro¹¹, ¹Università degli Studi di Genova, Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Genoa, Italy, ²IRCCS Istituto Giannina Gaslini, UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ³IRCCS Istituto Giannina Gaslini, UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁴University of Latvia, Pediatric Rheumatology, Riga, Latvia and University Children Hospital, Riga, Latvia, ⁵Shariati Hospital, Rheumatology Research Center, Department of Pediatrics and Rheumatology, Teheran, Islamic Republic of Iran, Teheran, Iran, ⁶University Children Hospital, University Medical Center Ljubljana, Department of Allergology, Rheumatology and Clinical Immunology, Ljubljana, Slovenia, ⁷Paris Cité Université and Necker Hospital, Paris, France, ⁸UOC Servizio di Sperimentazioni Cliniche Pediatriche, PRINTO, Genoa, Italy, ⁹Direzione Scientifica, IRCCS Istituto Giannina Gaslini, Genova, Italy, ¹⁰UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy, ¹¹Dipartimento di Neuroscienze, Riabilitazione, Oftalmologia, Genetica e Scienze Materno-Infantili (DiNOGMI), Università degli Studi di Genova and UOC Reumatologia e Malattie Autoinfiammatorie, Genoa, Italy
Background/Purpose: The measurement of disease activity level is of central importance in the evaluation of the patient with juvenile idiopathic arthritis (JIA). The Juvenile Arthritis…
Abstract Number: 0305 • ACR Convergence 2023
Prevalence and Clinical Significance of anti-Ro52 Antibodies in Antisynthetase Syndrome
Javier Narvaez¹, Paola Vidal-Montal², Elena Cañadillas-Sanchez³, Pol Maymó², Judith Palacios², Martí Aguilar², Montserrat Roig² and Joan Miquel Nolla², ¹Hospital Universitario de Bellvitge, Barcelona, Spain, ²Department of Rheumatology, Hospital Universitario de Bellvitge, Barcelona, Spain, ³Department of Rheumatology, Hospital Clínico Universitario Lozano Blesa, Zaragoza, Spain
Background/Purpose: Antisynthetase syndrome (ASSD) is a systemic autoimmune condition characterized by the positivity of anti-aminoacyl-transfer-RNA synthetases antibodies (ARS) and the occurrence of the classic triad,…
Abstract Number: 0373 • ACR Convergence 2023
Potential Tear-Based Uveitis Biomarkers in Children with JIA: A Pilot Study
Ilaria Maccora¹, Mekibib Altaye², Tiffany Nguyen³, Kenneth Greis⁴, Wendy Haffey⁴, Theresa Hennard⁵, Alyssa Sproles², Sherry Thornton², Virginia Miraldi Utz⁵ and Sheila Angeles-Han², ¹PhD student, in the Area of Drugs and Innovative Treatments, NeuroFARBA Department, University of Florence. Meyer Children's Hospital, Firenze, Italy, ²Cincinnati Children's Hospital, Cincinnati, OH, ³Cincinnati Eye Institute, Cincinnati, OH, ⁴University of Cincinnati, Cincinnati, OH, ⁵Cincinnati Children's Hospital Medical Center, Cincinnati, OH
Background/Purpose: Children with oligoarticular JIA are at increased risk of developing uveitis. JIA category, ANA positivity, ≤4 years JIA duration, and < 6 years old…
Abstract Number: 0374 • ACR Convergence 2023
Actionable Adverse Events in a Real-Practice Cohort of Children with Juvenile Idiopathic Arthritis. Results from the CAPRI Registry
Bashayer Alnuaimi¹, Michelle Batthish², Roberta A Berard³, Gilles Boire⁴, Sarah Campillo¹, Amieleena Chhabra⁵, Julie Couture⁶, Paul Dancey⁷, Brian Feldman⁸, Tommy Gerschman⁹, Julie Herrington¹⁰, Kristin Houghton¹¹, Adam Huber¹², Claire LeBlanc¹, Lillian Lim¹³, Jean-Philippe Proulx-Gauthier⁶, Heinrike Schmeling¹⁴, Rosie Scuccimarri¹, Lori Tucker¹⁵, Jaime Guzman¹⁵, Gaëlle Chédeville¹ and For The CAPRI Registry Investigators¹⁶, ¹McGill University Health Center, Montreal, QC, Canada, ²McMaster Children's Hospital, Hamilton, ON, Canada, ³Children's Hospital - London Health Sciences Centre, London, ON, Canada, ⁴Université de Sherbrooke, Sherbrooke, QC, Canada, ⁵British Columbia Hospital, Vancouver, BC, Canada, ⁶CHU de Quebec- Universite Laval, Quebec City, QC, Canada, ⁷Memorial University of Newfoundland, St. John's, NL, Canada, ⁸The Hospital for Sick Children, Toronto, ON, Canada, ⁹British Columbia Children's Hospital, Burnaby, BC, Canada, ¹⁰McMaster University, Hamilton, ON, Canada, ¹¹British Columbia University, Vancouver, BC, Canada, ¹²IWK Health Centre, Halifax, NS, Canada, ¹³University of Alberta, Edmonton, AB, Canada, ¹⁴University of Calgary, Calgary, AB, Canada, ¹⁵British Columbia Children's Hospital, Vancouver, BC, Canada, ¹⁶CAPRI, Montreal, QC, Canada
Background/Purpose: Juvenile idiopathic arthritis (JIA) is the most common chronic inflammatory rheumatic disease of childhood and most children require long-term treatment. Adverse events (AE) during…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].